Evidence map›Paper›PMID 41972234›Full record

ArticleSerican journal of medicine2026

Conditionally Reprogrammed Cells Preserve Cellular Diversity and Permit Genetic Manipulation: Implications for Cancer Heterogeneity and Tissue Regeneration.

Shuang Fang, Guangzhao Li, Dilber Nurmurmet, Xiaokui Mo, Chen Fei, Sujata Choudhury, Nancy Palechor-Ceron, Richard Schlegel, Xuefeng Liu, Jenny Li

Abstract read
In one paragraph

Article in Serican journal of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuang FangDepartment of Pathology, Georgetown University Medical Center, Washington, D.C. 20057, USA.
Guangzhao LiDepartment of Pathology, Georgetown University Medical Center, Washington, D.C. 20057, USA.
Dilber NurmurmetComprehensive Cancer Center, Wexner Medical Center, The Ohio State University, Columbus, Ohio 43210, USA.
Xiaokui MoDepartment of Biostatistics and Bioinformatics, Comprehensive Cancer Center, Wexner Medical Center, The Ohio State University, Columbus, Ohio 43210, USA.
Chen FeiDepartment of Pathology, Georgetown University Medical Center, Washington, D.C. 20057, USA.
Sujata ChoudhuryDepartment of Pathology, Georgetown University Medical Center, Washington, D.C. 20057, USA.
Nancy Palechor-CeronDepartment of Pathology, Georgetown University Medical Center, Washington, D.C. 20057, USA.
Richard SchlegelDepartment of Pathology, Georgetown University Medical Center, Washington, D.C. 20057, USA.
Xuefeng LiuDepartments of Pathology, Comprehensive Cancer Center, Wexner Medical Center, The Ohio State University, Columbus, Ohio 43210, USA.
Jenny LiDepartments of Pathology, Comprehensive Cancer Center, Wexner Medical Center, The Ohio State University, Columbus, Ohio 43210, USA.

Funding

Developing Functional Human Cell Models to Study Initiation and Progression of Prostate Cancer between AA and EA menR01CA276474 · NCI · OHIO STATE UNIVERSITY · PI Xuefeng Liu · 2023 to 2026
$2.1M
Conditionally Reprogrammed Cell Model for Castration-Resistant Prostate Cancer (CRPC)R01CA222148 · NCI · OHIO STATE UNIVERSITY · PI LIU, XUEFENG · 2019 to 2022
$1.9M
Evaluation of Pre-Analytical Factors of Urine Samples for Urine Cancer Cell Cultures (UCCC) --A Non-Invasive Biomarker – in Monitoring Response and Recurrence of Bladder CancerU01CA278927 · NCI · OHIO STATE UNIVERSITY · PI LIU, XUEFENG · 2023 to 2025
$1.8M
Validating Urine Derived Cancer Cells (UDCC) -- Non-Invasive and Living Liquid Biopsies -- in Bladder Cancer ClinicsR33CA258016 · NCI · OHIO STATE UNIVERSITY · PI LIU, XUEFENG · 2021 to 2023
$1.2M
NON-CANONICAL FUNCTIONS OF HTERT IN CELL IMMORTALIZATION BY HPVR21CA180524 · NCI · GEORGETOWN UNIVERSITY · PI LIU, XUEFENG · 2013 to 2014
$366k
NCI NIH HHS R01 CA222148NCI NIH HHS R01 CA276474NCI NIH HHS R21 CA180524NCI NIH HHS R33 CA258016NCI NIH HHS U01 CA278927
6 · The paper itself

Abstract

Our previous study demonstrated that a Rho kinase inhibitor (Y-27632), in combination with irradiated fibroblast feeder cells, enables both normal and tumor epithelial cells from various tissues to proliferate indefinitely in vitro, without the need for exogenous viral or cellular gene transduction. These cells are referred to as Conditionally Reprogrammed Cells (CRCs). This approach has shown great promise for applications in regenerative and personalized medicine. In the present study, we first investigated whether CRCs could be genetically manipulated and stably express exogenous genes. Using lentiviral transduction of GFP, we successfully infected human foreskin keratinocytes (HFKs) cultured under CRC conditions. GFP expression was stably maintained over multiple passages and through freeze-thaw cycles. Similar stable GFP expression was also observed in CRCs derived from human tumor specimens, including neuroendocrine cervical carcinoma and prostate cancer. We next explored the use of GFP-labeled CRC-HFKs in co-culture systems with tumor-derived CRCs to evaluate colony formation and cellular heterogeneity. Our data demonstrated that CRCs from different individuals can form heterogeneous colonies, supporting the potential of CRC-based systems for modeling tissue development, regeneration, and tumor heterogeneity. To optimize the CRC platform for translational applications, we further assessed human fibroblasts as an alternative to the mouse feeder layer, using GFP-expressing CRCs as a functional readout. Finally, we demonstrated the capacity for gene knockdown in CRCs by successfully silencing p53 and HPV16 E6 in cervical cancer-derived CRCs using shRNA lentiviral vectors. These results collectively establish that the CRC method supports stable genetic manipulation and underscore its potential for mechanistic studies, disease modeling, and development of cell-based therapeutic strategies.

Indexed as

cancer heterogeneityconditionally reprogrammed cells (CRC)patient-derived cell modelstissue repair

Identifiers

PMID41972234
PMCPMC13064450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.